Revenio Group Oyj (REG1V.HE) has a MoatMap StockRank of 55/100 based on Quality (76/100), Value (44/100), and Momentum (20/100) factor scores. The current signal is HOLD. Revenio Group is a high-quality medical technology company specializing in glaucoma screening. While it is an excellent business, it lacks any direct alignment with our 18-month macro themes.
Revenio Group Oyj is a global leader in ophthalmic diagnostics, specializing in non-invasive intraocular pressure measurement devices under the iCare brand. The company's competitive moat is secured by patented rebound tonometry technology and a dominant global market share in glaucoma screening. It is a highly profitable, niche medical technology leader with a strong recurring revenue stream from consumables.
| Price | $15.35 |
| Market Cap | $436M |
| P/E (TTM) | 23.76 |
| P/E (Forward) | 14.44 |
| Price/Book | 3.25 |
| Return on Equity | 13.7% |
| Return on Invested Capital | 18.6% |
| Debt/Equity | 9.21 |
| Gross Margin | 69.9% |
| Operating Margin | 8.4% |
| Revenue Growth | 4.6% |
| Dividend Yield | 2.0% |
| Free Cash Flow | $19M |
Revenio Group Oyj operates in the Medical Devices industry, part of the Healthcare sector (Finland).